Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL8391416 | 0.96 | AGTR1 (0.92) | AGTR1AGTR2 | |
| SCHEMBL8391160 | 0.93 | AGTR1 (0.86) | AGTR1AGTR2 | |
| SCHEMBL27539271 | 0.93 | AGTR1 (0.86) | AGTR1AGTR2 | |
| SCHEMBL8393396 | 0.92 | AGTR1 (0.84) | AGTR1AGTR2 | |
| SCHEMBL8944479 | 0.91 | AGTR2 (0.83) | AGTR1AGTR2 | |
| SCHEMBL8393366 | 0.90 | AGTR1 (0.82) | AGTR1AGTR2 | |
| SCHEMBL8392287 | 0.90 | AGTR1 (0.82) | AGTR1AGTR2 | |
| Trifluoroacetic Acid SCHEMBL8392194 | 0.90 | AGTR1 (0.82) | AGTR1AGTR2 | |
| SCHEMBL8391301 | 0.90 | AGTR1 (0.82) | AGTR1AGTR2 | |
| SCHEMBL6567320 | 0.90 | AGTR1 (0.82) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873904-B1 | TETRAHYDROPYRAN (THP)-SUBSTITUTED BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2024-07-10 | — | — | EP | claimed |
| US-20220340569-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | MYOKARDIA INC (US) | 2022-10-27 | — | — | US | claimed |
| EP-4054588-A1 | METHODS OF TREATMENT WITH MYOSIN MODULATOR | MyoKardia, Inc. (US) | 2022-09-14 | — | — | EP | claimed |
| CN-114945372-A | Methods of treatment with myosin modulators | 迈奥卡迪亚公司 | 2022-08-26 | — | — | CN | claimed |
| US-20220106314-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | MYOKARDIA INC (US) | 2022-04-07 | — | — | US | claimed |
| EP-0724387-B1 | ANGIOTENSION II RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC ANTI-INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORP (US) | 2003-05-02 | — | — | EP | claimed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | claimed |
| EP-0392317-B1 | Benzimidazoles, drugs containing these compounds and process for their preparation | THOMAE GMBH DR K (DE) | 1996-01-03 | — | — | EP | claimed |
| EP-0392317-A2 | Benzimidazoles, drugs containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1990-10-17 | — | — | EP | claimed |
| EP-4736855-A2 | TETRAHYDROPYRAN (THP)-SUBSTITUTED BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12616697-B2 | Methods of treatment with myosin modulator | MyoKardia, Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4464321-B1 | TETRAHYDROPYRAN (THP)-SUBSTITUTED BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250339395-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | NOVARTIS PHARMACEUTICALS CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250325531-A1 | TREATMENT OF SYSTOLIC DYSFUNCTION | MyoKardia, Inc. (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2022040246-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | STIMIT CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |
| EP-1014989-B1 | ENDOTHELIN ANTAGONIST AND A RENIN-ANGIOTENSIN SYSTEM INHIBITOR AS A COMBINED PREPARATION | ABBOTT GMBH & CO KG (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-6329384-B1 | CARDIOVASCULAR DISORDERS USING PYRAMIDINYLOXYDIPHENYL ALKYLCARBOXYLIC ACID | ABBOTT LABORATORIES | 2001-12-11 | — | — | US | disclosed |
| EP-0634175-B1 | Pharmaceutical combination, containing a renin-angiotensin-system inhibitor and an endothelin antagonist | HOFFMANN LA ROCHE (CH) | 2001-01-10 | — | — | EP | disclosed |
| US-5696116-A | TREATING DISORDERS ASSOCIATED WITH VASOCONSTRICTION | HOFFMANN-LA ROCHE INC. (US) | 1997-12-09 | — | — | US | disclosed |
| EP-0634175-A1 | Pharmaceutical combination, containing a renin-angiotensin-system inhibitor and an endothelin antagonist | F. HOFFMANN-LA ROCHE AG (CH) | 1995-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106314-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | DHPS, THPO, TNNI3 | AGTR1 1015/4885AGTR2 868/4885 |
| US-20220340569-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | DHPS, THPO, TNNI3 | AGTR1 1015/4885AGTR2 868/4885 |
| US-12616697-B2 | Methods of treatment with myosin modulator | MYH2, MYH14, MYH10 | AGTR1 528/4885AGTR2 228/4885 |
| US-20250325531-A1 | TREATMENT OF SYSTOLIC DYSFUNCTION | FABP3, TNNI3, TNNT2 | AGTR1 173/4885AGTR2 116/4885 |
| US-20250339395-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | MME, DNPEP, ANPEP | AGTR1 8/4885AGTR2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.